8-K: Pieris Pharmaceuticals Terminates Collaboration Agreement with Servier Following Safety Concerns

Pieris Pharmaceuticals has received notice of termination from Servier for their collaboration agreement due to safety concerns in a Phase 1 clinical study, leading to the discontinuation of a key drug program.

Summary

• Pieris Pharmaceuticals received a termination notice from Les Laboratoires Servier and Institut de Recherches Internationales Servier for their collaboration agreement, effective December 27, 2024.
• The termination is due to a potential safety concern identified in the Phase 1 clinical study of S095012, a 4-1BB/PD-L1 bispecific Mabcalin protein.
• Servier will discontinue dosing in the S095012 Phase 1 clinical study.
• Pieris does not intend to pursue further development of S095012.
• The company will review the safety data from the S095012 Phase 1 clinical study to understand the implications.
• Pieris remains eligible for potential milestone and royalty payments from its partnerships with Boston Pharmaceuticals and Pfizer, Inc.
• These potential milestones include up to $15 million upon first patient dosed in Phase 2 trials, $40 million upon first patient dosed in pivotal trials, and a total of $200 million in development milestones for two clinical stage assets in single, primary indications.
• Total commercial milestone potential on the same assets could exceed $415 million, with an additional $130 million possible if developed in additional indications.

Sentiment

Score: 3

Explanation: The document contains significant negative news regarding the termination of a key collaboration and the discontinuation of a drug program. While there are potential future milestones, the immediate impact is negative, leading to a low sentiment score.

Positives

• Pieris remains eligible for significant potential milestone and royalty payments from its partnerships with Boston Pharmaceuticals and Pfizer.
• The company has a strategy to maximize the potential of its partnered 4-1BB bispecific Mabcalin protein immuno-oncology assets.
• There is potential for over $600 million in total milestone payments from the Boston Pharmaceuticals and Pfizer partnerships.

Negatives

• The termination of the Servier collaboration agreement is a significant setback for Pieris.
• The discontinuation of the S095012 program removes a key asset from Pieris's pipeline.
• The termination was due to a potential safety concern in the S095012 Phase 1 clinical study.

Risks

• The company's cash runway may be reduced by unanticipated liabilities or decisions to opportunistically pursue strategic opportunities.
• There is uncertainty regarding the company's ability to be successful in exploring and consummating licensing or other transactions.
• The company's partners may decide not to prioritize or further pursue the programs that the company hopes to receive milestone and royalty payments under.
• Data and results from clinical studies may not necessarily be indicative of future results.
• The company may face challenges in continuing to comply with the listing standards of The Nasdaq Stock Market LLC.
• Delays or disruptions due to geopolitical issues, including the conflicts in Ukraine and the Middle East, could impact the company.
• Overall market conditions could affect the company's performance.

Future Outlook

The company will focus on maximizing the potential of its remaining partnered assets and exploring strategic opportunities, while also managing its cash runway and navigating potential risks.

Management Comments

• The Company intends to review the safety data from the S095012 Phase 1 clinical study to understand the implications of the data.
• The Company does not intend to pursue any further development of S095012.
• The Company continues to remain eligible to receive potential milestone and royalty payments across its remaining partnered 4-1BB bispecific Mabcalin protein franchise.

Industry Context

The termination of the collaboration agreement highlights the inherent risks in pharmaceutical development, particularly in immuno-oncology, where safety concerns can lead to the discontinuation of promising programs. This event may cause investors to re-evaluate the risk profile of companies relying on partnered programs.

Comparison to Industry Standards

• The termination of a collaboration agreement due to safety concerns is not uncommon in the pharmaceutical industry, with similar events impacting companies like Xencor and MacroGenics in recent years.
• The potential milestone payments of over $600 million are significant, but the actual realization of these payments is contingent on successful clinical trials and regulatory approvals, which is a common challenge for biotech companies.
• Companies like BioNTech and Moderna have demonstrated the potential for large milestone payments and commercial success in the immuno-oncology space, but also highlight the risks associated with clinical development and regulatory hurdles.

Stakeholder Impact

• Shareholders will likely react negatively to the termination of the collaboration agreement and the discontinuation of the S095012 program.
• Employees may experience uncertainty due to the changes in the company's pipeline.
• The termination may impact the company's relationships with its partners and collaborators.

Next Steps

• Pieris intends to review the safety data from the S095012 Phase 1 clinical study.
• The company will continue to pursue potential milestone and royalty payments from its partnerships with Boston Pharmaceuticals and Pfizer.
• Pieris will explore strategic opportunities to increase stockholder value.

Key Dates

Keywords

Pieris Pharmaceuticals, Servier, Collaboration Agreement, Termination, S095012, Anticalin, Immuno-oncology, Milestone Payments, Clinical Trials, Safety Concerns, Mabcalin, Boston Pharmaceuticals, Pfizer